Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Ipsen
Ipsen
ASCO: Exelixis releases more details on Cabometyx thyroid cancer data that wooed Ipsen
Fierce Pharma
Thu, 05/20/21 - 12:15 pm
ASCO 2021
Ipsen
Exelixis
Cabometyx
thyroid cancer
clinical trials
Exelixis' Cabometyx scores backing from Ipsen in thyroid cancer, with full data release set for ASCO
Fierce Pharma
Wed, 05/12/21 - 11:39 pm
Exelixis
Cabometyx
Ipsen
thyroid cancer
FDA Approvals Roundup: Qwo, Tremfya, Dysport
RAPS.org
Wed, 07/15/20 - 11:19 pm
FDA
drug approvals
Endo International
Qwo
cellulite
Ipsen
Dysport
cerebral palsy
Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 project
Fierce Pharma
Fri, 05/29/20 - 12:27 pm
Sanofi
Paul Hudson
David Loew
Ipsen
Pharma CEOs
FerGene
vaccines
Ipsen scraps pivotal trial as partial clinical hold drags on
Fierce Biotech
Thu, 03/26/20 - 10:40 am
Ipsen
palovarotene
clinical trials
osteochondromas
Spark, Ipsen and more join advocacy groups, agencies in Rare Disease Day 2020 efforts
Fierce Pharma
Fri, 02/28/20 - 11:50 pm
Spark Therapeutics
Ipsen
Rare Diseases
Ipsen takes €669M hit as palovarotene's prospects wither
Fierce Biotech
Thu, 02/13/20 - 10:47 am
Ipsen
palovarotene
Top Companies in Pharm Country Ranked by Revenue
BioSpace
Fri, 02/7/20 - 11:46 pm
Connecticut
New York
New Jersey
Pennsylvania
Rhode Island
Merck
Bristol-Myers Squibb
Regeneron
Ipsen
Ovid Therapeutics
Codagenix
Ipsen’s quick fix backfires
EP Vantage
Fri, 01/24/20 - 10:48 am
Ipsen
bone disease
palovarotene
Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns
Bloomberg
Fri, 12/6/19 - 09:50 am
Ipsen
Somatuline
FDA
fibrodysplasia ossificans progressiva
osteochondromas
Ipsen doubles down on rare bone disease
EP Vantage
Wed, 10/16/19 - 07:18 pm
Ipsen
FOP
BLU-782
Blueprint Medicines
Clementia Pharmaceuticals
FDA approves Ipsen’s Dysport to treat upper limb spasticity in children
Pharmaceutical Business Review
Fri, 09/27/19 - 09:43 am
Ipsen
Dysport
upper limb spasticity
FDA
Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Pharmaceutical Business Review
Mon, 07/8/19 - 10:25 am
Ipsen
Servier
liposomal irinotecan
pancreatic cancer
Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia
Endpoints
Mon, 02/25/19 - 10:04 am
M&A
Ipsen
Clementia Pharmaceuticals
Rare Diseases
FDA approves Cabometyx for liver cancer
BioCentury
Mon, 01/14/19 - 11:59 pm
Exelixis
Ipsen
Cabometyx
liver cancer
FDA
With New HQ, Ipsen to Rapidly Expand North American Presence
BioSpace
Sat, 11/17/18 - 12:59 pm
Ipsen
Kendall Square
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
CP WIre
Fri, 09/21/18 - 10:02 am
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Fri, 09/21/18 - 10:01 am
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Wed, 09/19/18 - 11:27 am
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Wed, 09/19/18 - 09:16 am
Exelixis
Ipsen
Cabometyx
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »